A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB-50465, a PI3K8 Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
May 10, 2018
End Date
December 27, 2023
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
May 10, 2018
End Date
December 27, 2023